ad image

Janssen Pharmaceuticals

1 / 1
physIQ
Digital Medicine

PhysIQ Announces Strategic Collaboration to Scale Digital Medicine

physIQ

PR-M04-21-019Apr 20, 2021
Janssen Reports Positive Results for DARZALEX® in Multiple Myeloma
Multiple Myeloma

Janssen Reports Positive Results for DARZALEX® in Multiple Myeloma

Emilie Branch

Pharma's Almanac

PAO-M12-19-NI-006Dec 13, 2019
Janssen Pharmaceutical Companies
FDA Approval

Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Janssen Pharmaceutical Companies

PR-M10-19-NI-032-2050Oct 22, 2019
nference
Strategic Partnership

nference Enters into an R&D Data Science Strategic Partnership with Janssen

nference

PR-M06-19-NI-013Jun 13, 2019
Janssen, Iktos Collaborate on In Silico Drug Design
Drug Design

Janssen, Iktos Collaborate on In Silico Drug Design

Emilie Branch

Pharma's Almanac

PAO-M05-19-NI-022May 21, 2019
Janssen Aims for Supplemental U.S. FDA Approval for INVOKANA®
FDA

Janssen Aims for Supplemental U.S. FDA Approval for INVOKANA®

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M04-19-NI-007Apr 02, 2019
Janssen Pharmaceutical Companies
New Drug Application

Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

Janssen Pharmaceutical Companies

PR-M04-19-NI-008Apr 02, 2019
Johnson & Johnson
HIV

Long-Acting Injectable HIV Treatment Regimen of Rilpivirine and Cabotegravir Demonstrated Comparable Safety and Efficacy to Daily Oral HIV Therapy

Johnson & Johnson

PR-M03-19-NI-033Mar 12, 2019
Xarelto Gets Approval for Additional Indication
Approval

Xarelto Gets Approval for Additional Indication

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M10-18-NI-019Oct 22, 2018
1 / 1